Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...

Advisers to the FDA will debate if the virus has mutated enough since last winter to require a tweak to the formula.

The FDA’s recent activities regarding Covid-19 vaccines stray far from the well-established standards of vaccine regulatory ...

The Food and Drug Administration (FDA) announced plans to significantly curtail people’s access to Covid-19 vaccines.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization. Health experts consider it a valuable alternative to messenger RNA shots ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization ...

This weekend, the FDA released its recommendation for Novavax, a vaccine designed to combat COVID-19. That in itself is not ...